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Abstract
Purpose: Most definitions of visual impairment focus on the status of the better-seeing eye only, but this approach
might underestimate the influence of the worse-seeing eye on the vision-related quality of life (VRQoL).
Methods: We assessed distance-corrected visual acuity in both eyes and VRQoL using the “National Eye Institute
25-Item Visual Function Questionnaire” (NEI VFQ-25) in the German population-based Gutenberg Health Study. We
calculated the Rasch-based visual functioning scale (VFS) and socioemotional scale (SES). We categorized the visual
acuity of the better-seeing eye (BE) and worse-seeing eye (WE) as follows: (1) no visual impairment (VI) (< 0.32
logMAR)), (2) mild VI (0.32–0.5 logMAR), and (3) moderate to severe VI (> 0.5 logMAR). Next, the subjects were
categorized as follows: both eyes with no VI (no/no), the better-seeing eye with no VI and the worse-seeing eye
with mild VI (no/mild), no VI/severe VI (no/severe), both eyes with mild VI (mild/mild), light VI/severe VI (mild/
severe), and both eyes with severe VI (severe/severe). We calculated the median scores for VFS and SES. We used
linear regression to estimate the combined influence of BE/WE on VFS and SES.
Results: We included 11,941 participants (49.9% female, age range: 35–74 years) with information on VRQoL and
visual acuity. The median VFS/SES scores were 90/100 (no/no VI group), 84/97 (no/mild group), 81/94 (no/severe
group), 70/90 (mild/mild group), 67/74 (mild/severe group), and 63/76 (severe/severe group). These differences
were supported by the regression analysis results.
Conclusion: Relying on the function of the better-seeing eye considerably underestimates the impact of visual
impairment on VRQoL.
Background
The assessment of visual impairment poses the analytical
challenge that both eyes could be affected differently.
Most common definitions of visual impairment meet this
challenge by focusing on the visual function of the
better-seeing eye only —e.g., the definition of blindness of
the World Health Organization and Global Burden of Dis-
ease Study [1, 2]. However, there is increasing evidence that
this approach underestimates the influence of the
worse-seeing fellow eye on visual function and vision-re-
lated quality of life (VRQoL) [3, 4]. The Melbourne Visual
Impairment Project showed that even unilateral vision loss
caused difficulties in reading and recognizing faces and in-
creased the risk of falling when away and becoming
dependent in persons aged 40 years and older [5]. Addition-
ally, there is evidence from outcome studies that patients
who underwent cataract surgery in both eyes reported
greater improvement in quality of life than patients who
underwent surgery in only one eye [6, 7]. Studies in patients
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with age-related macular degeneration showed that bilat-
eral manifestation is associated with lower VRQoL than
unilateral manifestation [8]. Finger et al. showed that cal-
culating patient reported utilizes based on the better-see-
ing eye only is likely to underestimate the impact of visual
impairment [4]. To further elucidate the contribution of
both eyes to VRQoL, we explored in a large population-
based sample whether VRQoL is different when stratifying
participants according to the visual acuity of their
better-seeing eye only and compared this to also consider-
ing the visual acuity of the fellow eye (e.g., the
worse-seeing eye). We hypothesize that there will be a
substantial impact of the worse-seeing eye on VRQoL.
Materials and methods
Study population
We analyzed a subsample of the Gutenberg Health Study
(GHS) with data on both visual acuity and VRQoL avail-
able. The GHS is a population-based, single-center, pro-
spective, cohort study at the medical center of the
Johannes Gutenberg University Mainz in Germany [9].
The population sample was randomly drawn via local resi-
dents’ registration offices and equally stratified by sex for
each decade of age. The baseline examination included
15,010 participants aged 35 to 74 years and was conducted
from 2007 to 2012. The examination consisted of an oph-
thalmological examination, general and cardiovascular ex-
aminations, and questionnaires and interviews. The
ophthalmic branch has been described in detail by Höhn
et al. [10]. Briefly, we conducted measurements of autore-
fraction and distance-corrected visual acuity, intraocular
pressure, visual field testing, pachy- and keratometry, and
posterior segment photography. We used the NEI
VFQ-25 to assess VRQoL. We included all participants
who completed this questionnaire and with available in-
formation on the visual acuity of both eyes.
VRQoL data acquisition and analysis
Vision-related QoL was assessed using the German ver-
sion of the NEI VFQ-25 [11, 12]. The German NEI
VFQ-25 has been assessed for its psychometric proper-
ties and was used by various studies [12–17]. The ques-
tionnaire was self-administered as a print-out at the
study site and completed using both eyes and reading
glasses, if necessary. We used the most common VRQoL
instrument and applied state-of-the-art techniques re-
mediating the known flaws—i.e., the violation of unidi-
mensionality and lack of interval-scaled measurements—
to analyze the NEI VFQ-25 data. We followed the sug-
gestions of Pesudovs to calculate the “visual functioning
scale (VFS)” and “socioemotional scale” (SES); both are
interval scaled (0 = worst to 100 = best) and based on the
Rasch-transformed individual-level NEI VFQ-25 data
[18, 19]. The developers of the questionnaire initially
proposed to calculate 12 subscores and one composite
VRQoL score (http://www.rand.org/health/surveys_tools/
vfq.html, last accessed 2018-03-27) [18]. Subsequent stud-
ies showed that this approach violates unidimensionality
and interval-level measurement, both important proper-
ties of an instrument measuring QoL [20–24]. Therefore,
we chose the Rasch-based approach described above, as
previously used by us and others [18, 19, 25, 26].
Ocular measurements
Objective refraction and distance-corrected visual acuity
were measured in both eyes using a Humphrey Auto-
mated Refractor/Keratometer (HARK) 599 (Carl Zeiss
AG, Jena, Germany) without cycloplegia, starting with
the right eye [10]. Distance-corrected visual acuity was
measured using the built-in Snellen charts, ranging from
20/400 to 40/20 (logMAR 1.3 to − 0.3). Below that visual
acuity, we used a visual acuity chart at a distance of one
meter up to 20/800 (logMAR 1.6), followed by counting
fingers, hand movements, and the light perception test.
The spherical equivalent was calculated as the spherical
correction value plus half of the cylindrical power. A his-
tory of eye disease was assessed in a short interview pre-
ceding the eye examination.
Sociodemographic characteristics
The socioeconomic status was based on income, educa-
tion and occupation and was defined according to the
German Health Update 2009 (GEDA), with a range from
3 (lowest) to 21 (highest) socioeconomic status [27].
Statistical analysis
For descriptive analyses, we calculated the mean of the
spherical equivalent of both eyes for every participant.
Visual acuity measurements were converted to logMAR
[28]. We categorized the visual acuity of the better-seeing
eye and worse-seeing eye as follows, with the thresholds
based on the WHO definition of visual impairment (VI):
(0) no VI (< 0.32 logMAR)), (1) mild VI (0.32–0.5 log-
MAR), and (2) moderate to severe VI (> 0.5 logMAR) [1,
4]. The subjects were then categorized in 6 groups accord-
ing to the VI categories of both eyes (Table 1).
We calculated the median and interquartile range for
both VFS and SES for each group. We used linear regres-
sion models to estimate the influence of the combination
of BE/WE on the VRQoL scores (reference group: no vis-
ual impairment in both eyes). We adjusted for age and sex
in the basic model and additionally for socioeconomic sta-
tus in a second model. Additionally, we calculated separ-
ate models for participants aged younger than 65 years
and those aged 65 years and older. We repeated the ana-
lyses restricted to participants without self-reported am-
blyopia. Amblyopia is characterized by reduced vision
since childhood and might have a different impact on
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VRQoL than visual impairment acquired in later life as af-
fected persons are used to having “one lazy eye” (i.e., only
one functioning eye) [29]. The VRQoL might additionally
be affected by other nonocular chronic diseases. There-
fore, we also calculated models restricted to participants
without the following chronic diseases: diabetes mellitus,
cardiovascular disease, peripheral artery disease, chronic
kidney disease, chronic liver disease, chronic obstructive
pulmonary disease, depression, and cancer. Due to the ex-
ploratory character of this analysis, p-values were not ad-
justed for multiple testing. The data were analyzed using
GNU R version 3.3.1 [30].
Results
Our sample consisted of 11,941 GHS participants (49.9%
female; median age: 54.7 years) who completed the ques-
tionnaire without missing items necessary to calculate
the VRQoL scales and with visual acuity of both eyes
available. Categorized by the better-seeing eye, n =
11,846 (99.2%) had no VI, n = 69 (0.6%) had mild VI,
and n = 26 (0.2%) had moderate to severe VI. The me-
dian VRQoL score of the visual functioning scale (VFS)
was 89.6 and that of the socioemotional scale (SES) was
100.0. Details of the study sample are shown in Table 2.
Characteristics stratified by sex are shown in the (Add-
itional file 1: Table S1).
Categorized only by the better eye, the median scores
for the VFS were 89.6 (no VI), 70.2 (mild VI), and 63.2
(moderate to severe VI) (Table 3). If the VI of the
worse-seeing eye was considered additionally, there was a
decrease of approximately four points per VI category in
the strata defined by the better-seeing eye (Tables 4 and 5,
Fig 1). Participants with no visual impairment in the
better-seeing eye and mild visual impairment in the fellow
eye had a 5.0-point lower VFS score than participants with
no visual impairment in both eyes (95% confidence inter-
val (CI) -6.0; − 4.1). Participants with no visual impairment
in the better-seeing eye and severe visual impairment in
the fellow eye had a 9.0-point lower VFS score than par-
ticipants with no visual impairment in both eyes (95% CI:
− 10.0; − 8.0). These estimates are from the regression
model adjusted for age, sex and socioeconomic status
(Table 6). Different adjustment sets or restrictions to a
subsample without general comorbidities or amblyopia re-
sulted in only minor changes in the estimates (Additional
files 2, 3, 4, 5, 6 and 7). For all regression coefficients in
the main analyses, p was below 0.0001.
The median scores for the SES were 100 (no VI), 88.4
(mild VI), and 76.3 (moderate to severe VI) (Table 3). If
the worse-seeing eye was considered additionally, there
was a decrease of approximately three points per VI cat-
egory in the stratum of no VI in the better-seeing eye (Ta-
bles 6 and 7, Fig. 2). In the stratum of the better-seeing
eye with mild VI, there was a decrease of 16 points.
Table 1 Cross-table illustrating the categorization of subjects
according to visual impairment of both eyes in the population-
based Gutenberg Health Study (2007–2012)
Worse-seeing eye:
No VI Mild VI Moderate/
severe
Better-
seeing eye:
No VI “b0/w0”, n =
11,021
“b0/w1”,
n = 430
“b0/w2”,
n = 395
Mild VI / “b1/w1”,
n = 35
“b1/w2”,
n = 34
Moderate/
severe VI
/ / “b2/w2”,
n = 26
BE Better-seeing eye, WE Worse-seeing eye, VI Vision impairment; no VI: < 0.32
logMAR, mild VI: 0.32–0.5 logMAR; moderate/severe VI: > 0.5 logMAR
Table 2 Characteristics of the study sample of the German
population-based Gutenberg Health Study (GHS) with visual
acuity of both eyes and NEI VFQ-25 data available
All
N 11,941
Age [y] 54.7 (11.1)
Women 49.9% (5958)
Socioeconomic status 13.1 (4.4)
Eye characteristics:
Mean spherical equivalent [dpt] −0.12 (−1.25/0.81)
Visual acuity (better eye) [logMAR] 0 (0/0.10)
Visual acuity (worse eye) [logMAR] 0 (0/0.22)
Contact lenses or glasses 89.2% (10646)
Distance glasses 68.0% (8116)
History of eye surgery 7.3% (876)
Glaucoma 2.3% (270)
Age-related macular degeneration 0.4% (51)
Amblyopia 9.9% (1186)
Vision-related quality of life:
Visual functioning scale (NEI VFQ-25) 89.6 (81.3/95.1)
Socioemotional scale (NEI VFQ-25) 100.0 (94.5/100.0)
Continuous variables were described by mean values and standard deviation,
and a skewed distribution was described by the median and interquartile
range. Discrete variables were described by relative and absolute frequencies.
Table 3 NEI VFQ-25 visual functioning scale scores and
socioemotional scale scores by categories of vision impairment
of the better-seeing eye only in the German population-based
Gutenberg Health Study (GHS), 2007–2012
Visual impairment of the
better-seeing eye
visual functioning
scale score (VFS)
socioemotional
scale score (SES)
No VI (n = 11,846) 89.6 (81.3/95.1) 100 (94.6/100)
Mild VI (n = 69) 70.2 (57.6/78.0) 88.4 (67.9/97.1)
Moderate/severe VI (n =
26)
63.2 (46.6/78.7) 76.3 (68.0/93.9)
Scores displayed as medians (interquartile range); VI Vision impairment; no VI:
< 0.32 logMAR, mild VI: 0.32–0.5 logMAR; moderate/severe VI: > 0.5 logMAR
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Participants with no visual impairment in the better-seeing
eye and mild visual impairment in the fellow eye had a
1.9-point lower SES score than participants with no visual
impairment in both eyes. Participants with no visual im-
pairment in the better-seeing eye and severe visual impair-
ment in the fellow eye had a 5.7-point lower SES score
than participants with no visual impairment in both eyes
(95% CI -6.4; − 5.0). These estimates were from the regres-
sion model adjusted for age, sex and socioeconomic status
(Table 7). The regression results also showed a substantial
contribution of both eyes on SES. Adjustment for different
potential confounders and excluding general comorbidities
did not substantially change the regression estimates. In the
subsample without amblyopia, the influence of a
worse-seeing eye with moderate/severe VI in addition to a
better-seeing eye with no VI was larger than that in the
whole sample, and the effect size was similar to mild VI in
both eyes (Additional files 2, 3, 4, 5, 6 and 7). For all regres-
sion coefficients in the main analyses, p was below 0.0001.
In addition to adjusting for age, we calculated separate
regression models for participants aged younger than 65
years and those aged 65 years and older. In the younger
group, the impact of VI on VFS scores was higher; in
both age groups, there was a substantial difference in
VFS scores between categories defined by VI of both
eyes. For the SES score, the decrease in the groups in-
cluding the better-seeing eye without visual impairment
was larger in the older participants. In the other VI
groups, the reduction was more substantial in the youn-
ger age group (Additional files 2, 3, 4, 5, 6 and 7).
Discussion
This study showed that the visual acuity of the worse-seeing
eye has an important impact on VRQoL in addition to the
impact of the better-seeing eye. In a large population-based
setting, we showed the additional influence of the worse-see-
ing eye on VRQoL measured by the most commonly used
VRQoL instrument, the NEI VFQ-25. The “one-eye ap-
proach”, although common, is very likely to neglect the pa-
tient’s perspective. Our results are in line with previous
studies. Finger et al. used the same VI categories to evaluate
the impact of the visual impairment of both eyes on
patient-reported preferences but did use two other instru-
ments instead of the NEI VFQ-25. There was no effect cap-
tured by generic EQ-5D, but the worse-seeing eye had an
additional impact on the Vision and Quality of Life Index
[4]. Varma et al. showed, in 5270 participants of the Los
Angeles Latino Eye Study, that the impacts of unilateral
moderate/severe VI and bilateral mild VI on VRQoL were
similar, considering that only VI of one eye would have
underestimated the real impact [31]. Hirneiss et al.
reviewed the influence of both eyes on VRQoL in the con-
text of treatment decisions based on 47 publications [3].
Despite the heterogeneity in study designs and methods ap-
plied to assess VRQoL, the authors conclude that treatment
of both the better-seeing and worse-seeing eye leads to a
benefit in the patients’ quality of life, contrary to the com-
mon assumption that the better-seeing eye mostly deter-
mines VRQoL [3]. There is evidence that, in age-related
macular degeneration (AMD), VRQoL is lower in subjects
with both eyes affected than in unilateral affected subjects.
Dong et al. estimated a difference of six points between
both groups when analyzing the NEI VFQ-25 scores [8].
Treatment of AMD leads to an improvement of VRQoL, as
shown with the NEI VFQ-25 questionnaire, regardless of
whether the better-seeing or worse-seeing eye was treated
[32–34]. For cataract surgery, multiple studies reported an
increase of VRQoL in subjects after cataract surgery of the
second eye [6, 35, 36]. Schuster et al. used Rasch-trans-
formed NEI VFQ-25 data from the GHS and reported that
VRQoL has a similar magnitude in bilateral phakic and
pseudophakic subjects, but monolateral pseudophakic
subjects have a 6-point lower VRQoL [37]. These results
underline the importance of considering both eyes when
assessing the impact of VI on patient-reported outcomes.
Table 4 NEI VFQ-25 visual functioning scale scores by
categories of vision impairment considering both the better-
seeing eye and worse-seeing eye of the German population-
based Gutenberg Health Study (GHS), 2007–2012
Worse-seeing eye
No VI (n =
11,021)
Mild VI (n =
465)
Moderate/
severe VI (n =
455)
Better-
seeing
eye
No VI 89.6 (81.4/
95.1), n =
11,021
84.0 (74.9/
89.6), n =
430
80.5 (68.0/89.5),
n = 395
Mild VI / 70.2 (62.5/
80.2), n = 35
66.8 (45.7/76.0),
n = 34
Moderate/
severe VI
/ / 63.2 (46.6/78.7),
n = 26
Scores displayed as medians (interquartile range), VI Vision impairment; no VI:
< 0.32 logMAR, mild VI: 0.32–0.5 logMAR; moderate/severe VI: > 0.5 logMAR
Table 5 NEI VFQ-25 socioemotional scale scores by categories
of vision impairment (by the better-seeing eye and worse-
seeing eye) of the German population-based Gutenberg Health
Study (GHS), 2007–2012
Worse-seeing eye
No VI (n =
11,021)
Mild VI (n =
465)
Moderate/
severe VI (n =
455)
Better-
seeing
eye
No VI 100 (95.1/100),
n = 11,021
97.1 (91.2/
100), n = 430
94.1 (85.8/100),
n = 395
Mild VI / 90.1 (72.4/
97.1), n = 35
73.7 (67.5/95.2),
n = 34
Moderate/
severe VI
/ / 76.3 (68.0/93.9),
n = 26
Scores displayed as medians (interquartile range); VI Vision impairment; no VI:
< 0.32 logMAR, mild VI: 0.32–0.5 logMAR; moderate/severe VI: > 0.5 logMAR)
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Fig. 1 Distribution of NEI VFQ-25 visual functioning scale scores by categories of vision impairment (by the better-seeing eye and worse-seeing
eye) of the German population-based Gutenberg Health Study (GHS), 2007–2012. b: better-seeing eye; w: worse-seeing eye; 0: no visual
impairment (< 0.32 logMAR), 1: mild vision impairment (0.32–0.5 logMAR); 2: moderate/severe vision impairment (> 0.5 logMAR); gray boxes:
interquartile range (IQR); black line: median; black square: mean; whiskers: lowest data point still within 1.5 (IQR) of the lower quartile, and the
highest data point still within 1.5 IQR of the upper quartile; dots: outliers
Table 6 Linear regression estimates of the influence of both
the better-seeing and worse-seeing eyes on the NEI VFQ-25
visual functioning scale score in the German population-based
Gutenberg Health Study (GHS), 2007–2012
Category of visual impairment
considering better-seeing and
worse-seeing eye
Model 1a Model 1b
(n = 11,941,
R2 = 0.12)
(n = 11,889,
R2 = 0.12)
Estimate (CI) Estimate (CI)
BE no VI, WE mild VI −5.2a −5.0a
(−6.1; −4.2) (−6.0; −4.1)
BE no VI, WE moderate/ severe VI −9.03a −9.01a
(−10.0; −8.0) (−10.0; −8.0)
BE mild VI & WE mild VI −14.3a − 14.5a
(−17.6; − 11.0) (− 17.8; − 11.1)
BE mild VI & WE moderate/ severe
VI
−24.3a −24.1a
(−27.7; − 21.0) (− 27.4; -20.8)
BE moderate/ severe VI, WE
moderate/ severe VI
− 25.3a − 24.4a
(−29.1; − 21.5) (− 28.3; −20.5)
BE Better-seeing eye, WE Worse-seeing eye, VI Vision impairment; no VI: < 0.32
logMAR, mild VI: 0.32–0.5 logMAR; moderate/severe VI: > 0.5 logMAR); all
models adjusted for age and sex using both eyes with no VI as a reference;
model 1b additionally adjusted for socioeconomic status; CI: 95% confidence
interval; a: p < 0.0001, R2: adjusted R2
Table 7 Linear regression estimates of the influence of both
the better-seeing and worse-seeing eyes on the NEI VFQ-25
socioemotional scale score in the German population-based
Gutenberg Health Study (GHS), 2007–2012
Category of visual impairment
considering better-seeing and
worse-seeing eye
Model 1a Model 1b
(n = 11,941,
R2 = 0.09)
(n = 11,889,
R2 = 0.09)
Estimate (CI) Estimate (CI)
BE no VI, WE mild VI −2.0a − 1.9a
(−2.6; −1.3) (−2.6; − 1.2)
BE no VI, WE mild VI −5.7a − 5.7a
(−6.4; − 5.0) (− 6.4; − 5.0)
BE mild VI & WE mild VI − 10.4a −9.6a
(−12.8; − 8.1) (− 12.0; −7.2)
BE mild VI & WE moderate/ severe
VI
− 16.0a −15.9a
(−18.4; −13.6) (− 18.3; − 13.5)
BE moderate/ severe VI, WE
moderate/ severe VI
−20.9a −19.8a
(−23.6; − 18.2) (−22.6; − 17.1)
BE Better-seeing eye, WE Worse-seeing eye, VI Vision impairment; no VI: < 0.32
logMAR, mild VI: 0.32–0.5 logMAR; moderate/severe VI: > 0.5 logMAR; all
models adjusted for age and sex using both eyes with no VI as reference;
model 1b additionally adjusted for socioeconomic status; CI: 95% confidence
interval; a: p < 0.0001, R2: adjusted R2
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There is no minimal clinically important difference
(MCID) for Rasch-transformed NEI VFQ-25 scores; how-
ever, because the scale range is similar to the traditional
scale ranges (both 0–100 points), the MCID magnitude is
expected to be similar. The MCID for traditional NEI
VFQ-25 scores is estimated to be four to six points [38, 39].
The strengths of our study are the large sample size com-
bined with the population-based sampling. The broad as-
sessment of phenotype information is based on a
standardized study design and quality controls. Despite the
population-based sampling, individuals with bilateral visual
impairment are likely to be underrepresented in the GHS
cohort because of their lower likelihood to participate. Fur-
thermore, we had a considerable share of participants who
did not complete the NEI VFQ-25. At the beginning of the
GHS, participants were asked to complete the question-
naire at home. This was then changed to an on-site proced-
ure that greatly increased the rate of participation.
Participants with missing NEI VFQ-25 had a reduced phys-
ical health, but this seems to be mostly related to general
health and less to self-reported eye diseases and ocular pa-
rameters [19]. Therefore, we assume the bias due to miss-
ing information on VRQoL to be small. Additionally, the
numbers in the groups with advanced stages or VI are low,
and most participants had no VI. This was to be expected,
given the low prevalence of VI in European populations
below the age of 75 years and in our population-based
study sample [40]. This leads to a reduced precision of the
estimates in the groups with advanced stages of VI. Never-
theless, we could show an additional impact on VRQoL of
the worse-seeing eye compared with considering the
better-seeing eye only. Because the GHS includes a recall
every 5 years, we are planning to rerun the analyses in a
10-year older population in the future, where we expect a
higher prevalence in VI and to see even more distinct
results.
Conclusion
In summary, we demonstrate in a large population-
based study that the visual acuity of the worse-seeing
eye has an important impact on VRQoL, in addition
to the impact of the better-seeing eye. Whenever pos-
sible, the function of both eyes should be considered
in medical decision making, as well as in clinical,
health care and public health research.
Fig. 2 Distribution of NEI VFQ-25 socioemotional scale scores by categories of vision impairment (by better-seeing eye and worse-seeing eye) of
the German population-based Gutenberg Health Study (GHS), 2007–2012. b: better-seeing eye; w: worse-seeing eye; 0: no vision impairment (<
0.32 logMAR), 1: mild vision impairment (0.32–0.5 logMAR); 2: moderate/severe vision impairment (> 0.5 logMAR); gray boxes: interquartile range
(IQR); black line: median; black square: mean; whiskers: lowest data point still within 1.5 (IQR) of the lower quartile, and the highest data point still
within 1.5 IQR of the upper quartile; dots: outliers
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